Clinical Trial Update: BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115 [Phase 3]

View source ↗

Summary

A Phase 3 continuation study in systemic lupus erythematosus and an open-label extension completion for HGS1006-related trials; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• BEL113750
• BEL114333
• HGS1006-C1115

Snippet

Sponsor: GlaxoSmithKline | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: COMPLETED | Results posted: 2020-01-09